Related Experiment Video
Updated: Mar 2, 2026
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
The Alzheimer's Prevention Clinic at Weill Cornell Medical College / New York - Presbyterian Hospital: Risk
1Department of Neurology, Division of Memory Disorders, Weill Cornell Medical College / New York-Presbyterian Hospital, New York, NY, USA.
Insights
The first US Alzheimer's Prevention Clinic offers personalized plans to lower Alzheimer's disease (AD) risk using precision medicine. This approach aims to delay symptom onset and prepare individuals for future clinical trials.
Area of Science:
- Neuroscience
- Gerontology
- Preventive Medicine
Background:
- Alzheimer's disease (AD) poses a significant public health challenge.
- There is a growing need for proactive strategies to mitigate AD risk.
- Family history is a key risk factor for developing AD.
Purpose of the Study:
- To establish the first Alzheimer's Prevention Clinic (APC) in the US.
- To provide comprehensive, personalized risk reduction strategies for individuals at high risk for AD.
- To facilitate the development of a cohort for future AD prevention trials.
Main Methods:
- Utilizing pharmacogenomics, nutrigenomics, and precision medicine for tailored therapies.
- Conducting comprehensive assessments including anthropometrics, cognition, and biomarkers (lipid, inflammatory, metabolic, nutritional, genetic).
- Employing validated and emerging clinical and research technologies for longitudinal monitoring.
- Providing patient education through an interactive online course and cognitive testing.
Main Results:
- The APC offers direct clinical care and personalized prevention plans.
- Longitudinal data collection includes a wide range of health metrics.
- Patients receive education and tools to manage their brain health and reduce AD risk.
- A cohort of at-risk individuals is being established for future research.
Conclusions:
- The APC represents a novel, proactive approach to Alzheimer's disease prevention.
- Personalized medicine strategies can be applied to reduce modifiable AD risk factors.
- The clinic aims to delay symptom onset and empower individuals in managing their brain health.
- The established cohort will be crucial for advancing AD prevention research.
Abstract:
In July 2013, Weill Cornell Medical College founded the first Alzheimer's Prevention Clinic (APC) in the United States, providing direct clinical care to family members of patients with Alzheimer's disease (AD) as part of the Weill Cornell Memory Disorders Program. At the APC, patients seeking to lower their AD risk undergo a comprehensive assessment, receive a personalized plan based on rapidly evolving scientific evidence, and are followed over time using validated as well as emerging clinical and research technologies. The APC approach applies the principles of pharmacogenomics, nutrigenomics and clinical precision medicine, to tailor individualized therapies for patients. Longitudinal measures currently assessed in the clinic include anthropometrics, cognition, blood biomarkers (i.e., lipid, inflammatory, metabolic, nutritional) and genetics, as well as validated, self-reported measures that enable patients to track several aspects of health-related quality of life. Patients are educated on the fundamental concepts of AD prevention via an interactive online course hosted on Alzheimer's Universe (www.AlzU.org), which also contains several activities including validated computer-based cognitive testing. The primary goal of the APC is to employ preventative measures that lower modifiable AD risk, possibly leading to a delay in onset of future symptoms. Our secondary goal is to establish a cohort of at-risk individuals who will be primed to participate in future AD prevention trials as disease-modifying agents emerge for testing at earlier stages of the AD process. The clinical services are intended to lower concern for future disease by giving patients a greater sense of control over their brain health.
